Yoshiyama Annie 4

What Happened

• Annie Yoshiyama, Senior Vice President, Finance at Allogene Therapeutics (ALLO), received awards totaling 230,518 restricted stock units (RSUs) on 2026-02-02 (179,691 RSUs + 50,827 RSUs). These are derivative awards (no cash paid) and will convert to common shares if and when they vest. On the same date she sold 4,167 shares in an open-market transaction at a weighted-average price of $1.72 for proceeds of $7,167. The sale was to satisfy tax withholding obligations and was not a discretionary sell.

Key Details

• Transaction date: February 2, 2026; Form 4 filed February 4, 2026 (appears timely).
• Sale: 4,167 shares disposed, weighted-average price $1.72 (sales ranged $1.71–$1.74), proceeds $7,167. (Footnote F2: weighted avg; full per-lot prices available on request.)
• Awards: 179,691 RSUs and 50,827 RSUs granted (total 230,518 RSUs); reported price $0.00 (derivative awards).
• Vesting/other schedules: RSUs vest in four equal annual installments beginning Feb 2, 2026 (Footnote F5). A separate option vesting schedule is noted in the filing (25% vest Feb 2, 2027, then monthly over 36 months — Footnote F4). Footnote F3 notes prior ESPP purchase of 3,826 shares on Sept 15, 2025.
• Reason for sale: Footnote F1 states the 4,167-share sale was a mandated "sell to cover" to satisfy tax withholding — not a discretionary sale by the insider.
• Shares owned after transaction: not specified in the summary data provided.

Context

• RSUs are contingent rights to receive shares upon vesting; these grants are not immediate share purchases and vest over time (so they are not a same-day bullish cash purchase).
• The small, mandated sell was solely for tax withholding, which is common and does not by itself indicate a change in insider sentiment.
• Filing appears timely (filed two days after the transaction), so no late-filing flag.